2.Effect of hepatic arterial infusion chemotherapy combined with sintilimab and bevacizumab for treatment of advanced hepatocellular carcinoma with lenvatinib failure
Shuheng YANG ; Changhua JIANG ; Wanjun JIAN ; Qiaomu LUO
Chongqing Medicine 2024;53(21):3257-3263
Objective To explore the applicability,safety and effectiveness of hepatic arterial infusion chemotherapy(HAIC)combined with sintilimab and bevacizumab in the patients with intermediate and ad-vanced hepatocellular carcinoma(HCC)failed by lenvatinib treatment.Methods A total of 62 patients with intermediate and advanced liver cancer failed by lenvatinib treatment in this hospital from February 2023 to February 2024 were selected as the study subjects and divided into the HAIC group(n=13),HAIC+targeted therapy group(n=18)and HAIC+combined therapy group(n=31)according to different treatment regi-mens.The HAIC group only received the HAIC treatment,the HAIC+targeted therapy group adopted the HAIC+lenvatinib combined treatment and the HAIC+combined treatment group received the HAIC+sintil-imab and bevacizumab combined treatment.The objective remission rate(ORR),disease control rate(DCR),median progression-free survival time(mPFS),median overall survival time(mOS),carcinoembryonic antigen(CEA),vascular endothelial growth factor(VEGF),carbohydrate antigen 125(CA125)levels after treatment were observed in 3 groups,and the treatment related adverse reactions were recorded.The Kaplan-Meier method was used for conducting the survival analysis.Results According to RECIST1.1 criteria,ORR of the HAIC+combined treatment group was higher than that of the HAIC group and HAIC+targeted therapy group(35.5%vs.23.1%vs.22.2%),DCR was lower than that of the other two groups(83.8%vs.92.3%vs.88.9%),but the differences were not statistically significant and the differences were not statistically sig-nificant(P>0.05).mOS of the HAIC+combined treatment group was longer than that of the HAIC group and HAIC+targeted therapy group[18.1(95%CI:13.3-22.9)months vs.12.6(95%CI:9.0-16.2)months vs.15.9(95%CI:11.5-20.3)months].mPFS in the HAIC+combined treatment group was longer than that in the the HAIC group and HAIC+targeted therapy group[12.0(95%CI:9.4-14.6)months vs.9.7(95%CI:2.2-17.2)months vs.10.1(95%CI:8.3-11.9)months],and the differences were not statistically sig-nificant(P>0.05).The levels of CEA,VEGF and CA125 after treatment in 3 groups were decreased com-pared with before treatment,moreover the levels in the HAIC+combined treatment group was the lowest(P<0.05).There was no statistically significant difference in the incidence rate of adverse reactions among the three groups(P>0.05).Conclusion The HAIC combined with immunotherapy regimen is effective in the pa-tients with intermediate and advanced HCC failed by lenvatinib treatment,moreover which has high safety.
3.Cross-sectional study on comorbidities in community patients with stroke in Songjiang District, Shanghai
Minhua TANG ; Shuheng CUI ; Kangqi YI ; Yiling WU ; Yuting YU ; Qi ZHAO ; Genming ZHAO ; Yonggen JIANG
Shanghai Journal of Preventive Medicine 2022;34(9):888-894
ObjectiveTo investigate the comorbidity of community patients with stroke in Songjiang District, Shanghai, determine the prevalence and characteristics of comorbidities and influencing factors, and provide scientific evidence for prevention and treatment of stroke. MethodsA natural population-based cohort study was conducted in several communities of Songjiang District from April 2016 to October 2017. Questionnaire survey, physical examination and biochemical examination were conducted in the cohort population to understand the comorbidity of 1 523 patients with stroke at baseline. ResultsThe prevalence of comorbidities in community patients with stroke was 74.0%, which was higher in female (76.36%) than that in male (70.76%). The average number of comorbidities was 2.62±1.56, which was significantly higher in female (2.70±1.58) than that in male (2.52±1.54) (t=-2.31, P=0.021). In this population, the most common two-comorbidity combination was hypertension+central obesity (35.85%), and the most common three-comorbidity combination was hypertension+dyslipidemia+central obesity (17.20%), with statistically significant differences by gender and age groups (P<0.05). Multivariate analysis showed that age ≥65 years, urban population, hyperhomocysteinemia (HHcy), and family history of hypertension were risk factors associated with comorbidities, whereas educational level of middle school and high school, and physical exercise 1‒3 days per week were protective factors. ConclusionPrevalence of comorbidity is high in community patients with stroke in Songjiang District, Shanghai. It is suggested to control blood pressure and body weight, adopt healthy lifestyle and take comprehensive prevention and treatment measures in this population.
4.Association of hyperuricemia with risk of incident chronic kidney disease in adult in Songjiang district, Shanghai: a follow-up study
Yun QIU ; Qi ZHAO ; Na WANG ; Shuheng CUI ; Yuting YU ; Yonggen JIANG ; Genming ZHAO
Chinese Journal of Epidemiology 2021;42(9):1607-1614
Objective:To evaluate the association of hyperuricemia with the risk for chronic kidney disease (CKD) in community adults.Methods:A community-based follow-up study comprising of 7 276 adults aged 20-74 years who attended the natural population cohort in Eastern China and had no CKD at baseline survey was performed in the Songjiang district, Shanghai. CKD was diagnosed according to the National Kidney Foundation Practice Guidelines for Chronic Kidney Disease criteria. Hyperuricemia was defined as serum uric acid level >420 μmol/L for men and >360 μmol/L for women. Cox proportional hazards model was used to examine the association of hyperuricemia with the risk for CKD.Results:During a median follow-up period of 2.65 year, 301 participants were newly diagnosed with CKD. The cumulative incidence rate and incidence density of CKD were 4.14%, and 16.01/1 000 person-years (95% CI: 14.20-17.82), respectively. A higher prevalence of hyperuricemia was observed in subjects with CKD compared with those without CKD. Multivariate Cox regression model analysis showed that hyperuricemia was associated with the increased risk for CKD, with an adjusted HR of 1.92 (95% CI: 1.46-2.53). Their positive associations remained in almost all the subgroups, including sex, age (<60, ≥60 years), BMI (<25.0, ≥25.0 kg/m 2), type 2 diabetes, and hypertension. A significant synergistic effect of the interaction between age and hyperuricemia on CKD was found, and the synergy index was 1.78 (95% CI: 1.18-2.68). Conclusion:The incidence of CKD in adults in Songjiang district was relatively high. Hyperuricemia is an independent risk factor for the development of CKD.
5.Taurine attenuated ?-glycerophosphate-stimulated calcification in cultured rat vascular smooth muscle cells
Baohong ZHANG ; Zhisheng JIANG ; Shuheng WANG ; Dadi NIU ; Yongzheng PANG ; Juxiang LI ; Chaoshu TANG ; Junba DU
Chinese Journal of Pathophysiology 1986;0(02):-
AIM: To investigate the effect of taurine on calcification of vascular smooth muscle cells (VSMCs).METHODS: Calcified VSMCs of rat in vitro were induced by ?-glycerophosphate. Cellular calcium content,alkaline phosphatase(ALP) activities and accumulation were measured. DNA synthesis were evaluated by -thymidine (-TdR) incorporation. RESULTS: Calcium content,ALP activities and uptake of calcified VSMCs stimulated by taurine (5-20 mmol/L) were greatly decreased in a concentration-dependent manner as compared with calcified group ( P

Result Analysis
Print
Save
E-mail